Relay Therapeutics (RLAY) Accumulated Expenses (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Accumulated Expenses data on file, last reported at $20.9 million in Q1 2026.

• Quarterly Accumulated Expenses changed 0.37% year-over-year to $20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.9 million (changed 0.37% YoY) and the FY2025 annual result came in at $13.6 million, down 35.75% from the prior year.
• Accumulated Expenses grew to $20.9 million in Q1 2026 per RLAY's latest filing, from $13.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $33.2 million in Q3 2024 and bottomed at $13.6 million in Q4 2025.
• The 5-year median for Accumulated Expenses is $22.7 million (2022), against an average of $23.5 million.
• The widest annual swing landed in 2023, when Accumulated Expenses surged 84.3%; it then tumbled 35.75% in 2025.
• Tracing RLAY's Accumulated Expenses over 5 years: stood at $22.7 million in 2022, then sank by 34.41% to $14.9 million in 2023, then jumped by 42.62% to $21.2 million in 2024, then plunged by 35.75% to $13.6 million in 2025, then soared by 53.26% to $20.9 million in 2026.
• Per Business Quant, the three latest RLAY Accumulated Expenses figures stand at $20.9 million (Q1 2026), $13.6 million (Q4 2025), and $25.1 million (Q3 2025).

Peer Comparison